UBS Starts Abbvie (ABBV) at Neutral
Tweet
Share
E-mailGet Alerts ABBV Hot Sheet
Price: $244.78 +0.71%
Rating Summary:
26 Buy, 12 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 22 | New: 39
Rating Summary:
26 Buy, 12 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 22 | New: 39
Join SI Premium – FREE
Earlier, UBS initiated coverage on Abbvie (NYSE: ABBV) with a Neutral rating and $36 price target.
The firm comments, "Our thesis is three-fold: (1) Humira should be durable but competition from oral therapies and generics for now will remain a concern for investors. (2) Earnings in 2013/2014 will be held down by ~$2.5-3B sales hit from its lipid and HIV franchises going generic. (3) The late stage pipeline doesn’t kick in until 2015-16 and it’s still unclear how big its most important asset, the HCV franchise, will be given how quickly market dynamics are changing."
EPS estimates are $3.08 for 2013 and $3.20 for 2014. 5 year CAGRs are 1% for revenues and 2% for EPS.
For an analyst ratings summary and ratings history on Abbvie click here. For more ratings news on Abbvie click here.
Shares of Abbvie closed at $34.00 yesterday.
The firm comments, "Our thesis is three-fold: (1) Humira should be durable but competition from oral therapies and generics for now will remain a concern for investors. (2) Earnings in 2013/2014 will be held down by ~$2.5-3B sales hit from its lipid and HIV franchises going generic. (3) The late stage pipeline doesn’t kick in until 2015-16 and it’s still unclear how big its most important asset, the HCV franchise, will be given how quickly market dynamics are changing."
EPS estimates are $3.08 for 2013 and $3.20 for 2014. 5 year CAGRs are 1% for revenues and 2% for EPS.
For an analyst ratings summary and ratings history on Abbvie click here. For more ratings news on Abbvie click here.
Shares of Abbvie closed at $34.00 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Conagra Brands falls on weak fiscal 2027 earnings outlook
- Progressive Corp. (PGR) Reports Q2 EPS of $5.67
- Abbvie (ABBV) PT Raised to $300 at BMO Capital
Create E-mail Alert Related Categories
New CoverageRelated Entities
UBS, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
